Zobrazeno 1 - 10
of 44
pro vyhledávání: '"E. González-Colominas"'
Autor:
Santiago Grau, Marc Batlle, Marta de Antonio-Cuscó, Anna Viu, Xavier Bessa, E González-Colominas, José A. Carrión, Xavier Duran, Inés Monge-Escartín
Publikováno v:
European Journal of Gastroenterology & Hepatology. 32:214-222
BACKGROUND AND AIM Patients with chronic hepatitis C (CHC) frequently associated comorbidities and concomitant medication. Sustained virological response (SVR12) has been related to an increase in cholesterol serum levels and in peripheral vascular r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8fae01126249944a39e8698743e3b0b
https://doi.org/10.1097/meg.0000000000001714
https://doi.org/10.1097/meg.0000000000001714
Autor:
Javier Martínez-Casanova, E González-Colominas, Jason A. Roberts, Luisa Sorlí, Nuria E. Campillo, Francisco Álvarez-Lerma, Juan Pablo Horcajada, Sonia Luque, Daniel Echeverría-Esnal, Santiago Grau, Rosana Muñoz-Bermudez
Publikováno v:
Therapeutic Drug Monitoring. 41:732-739
BACKGROUND: Limited data regarding altered linezolid pharmacokinetics in patients with liver cirrhosis are available. The objective of this study was to evaluate the pharmacokinetics, efficacy and safety of linezolid in cirrhotic patients. METHODS: A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1ccb5e53e26b396e64ca9a4c9f3c54
https://doi.org/10.1097/ftd.0000000000000665
https://doi.org/10.1097/ftd.0000000000000665
Autor:
X Fernández-Sala, L. Comella-Anaya, Jaime Barceló-Vidal, E González-Colominas, C. López-Mula, Olivia Ferrández, P Acin, Sonia Luque, Daniel Echeverría-Esnal, N Carballo, M De Antonio-Cuscó
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Drug related problems (DRP) are common among hospitalised patients. During the COVID-19 pandemic, the number of inpatients increased and the pattern of drug use was varied which could lead to a higher number of potential DRP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aada10311aa6ae7a06e527352222783
https://doi.org/10.1136/ejhpharm-2021-eahpconf.216
https://doi.org/10.1136/ejhpharm-2021-eahpconf.216
Autor:
N. Carballo, J Monfort, O. Ferrández-Quirante, L Río-No, S. Grau-Cerrato, E. González-Colominas, C. Pérez, A Rodriguez
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Patient adherence is a key determinant of treatment success in rheumatological immunomediated diseases. Available data about adherence to biological treatments and factors associated with non-adherence are limited in Spain.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd219b270557e32c566902f457e8e6c3
https://doi.org/10.1136/ejhpharm-2021-eahpconf.223
https://doi.org/10.1136/ejhpharm-2021-eahpconf.223
Autor:
E González-Colominas, L Recasens, Santiago Grau, A Oliveras, J Pedro-Botet, R. González, Sonia Luque, A Rodriguez, C Lopez, L Tarason
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Alirocumab is a monoclonal antibody approved for the treatment of hypercholesterolaemia but long term clinical data are still limited. Aim and objectives To assess the long term efficacy, safety and adherence to alirocumab a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f748a19c465b24d97d0684b573f3aa09
https://doi.org/10.1136/ejhpharm-2020-eahpconf.124
https://doi.org/10.1136/ejhpharm-2020-eahpconf.124
Autor:
Adolfo Gallego, José A. Carrión, Xavier Torras, Rosa Maria Morillas, E González-Colominas, Sergi Mojal, María-Carlota Londoño, Neus Pagès, Zoe Mariño, Mercè Ardèvol, Ricard Solà, Dulce López, Sabela Lens
Publikováno v:
Journal of Gastroenterology and Hepatology. 33:1100-1107
Background & Aims Drug-drug interactions (DDIs) with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin (OBV/PTV/r ± DSV ± RBV) are common in clinical trials. Our aim was to analyze the prevalence and manageme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77990c67f35c7cc82eba0f7b9dfa939d
https://doi.org/10.1111/jgh.14014
https://doi.org/10.1111/jgh.14014
Autor:
William W. Hope, Santiago Grau, E González-Colominas, Nuria Campillo, Sonia Luque, Milagro Montero, R. Muñoz-Bermúdez, Luisa Sorlí, J.P. Horcajada, J. Barceló-Vidal, Francisco Álvarez-Lerma, Joan R. Masclans
Publikováno v:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3519f32bd1c684c16775540dd596735
https://doi.org/10.1128/aac.00378-19
https://doi.org/10.1128/aac.00378-19
Autor:
M Ferran, E González-Colominas, F Gallardo, X Fernández-Sala, Olivia Ferrández, E Beltrán, Santiago Grau, L Tarrasón, N Carballo, R Gonzalez, E Navarrete Rouco
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background A limited number of studies have evaluated medication adherence in psoriasis (PS) or psoriatic arthritis (PsA), reporting rates between 29% and 88% (medication possession ratio (MPR >80%)). However, until now no study has included apremila
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c808a4d3a24304a11a4bc0efde8b94ea
https://doi.org/10.1136/ejhpharm-2019-eahpconf.185
https://doi.org/10.1136/ejhpharm-2019-eahpconf.185
Autor:
X Fernández-Sala, Sonia Luque, M De Antonio, E González-Colominas, Santiago Grau, P Acin, Hernando Knobel
Publikováno v:
Section 6: Education and Research.
Background Current guidelines recommend starting antiretroviral treatment (ART) in all HIV-infected patients irrespective of the CD4 count.1 Some studies have described that more than 40% of patients switch their initial ART.2 Purpose To describe ini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::648d95904342736d186a2667ce62dffa
https://doi.org/10.1136/ejhpharm-2019-eahpconf.605
https://doi.org/10.1136/ejhpharm-2019-eahpconf.605
Autor:
L Recasens, I Monge, E González-Colominas, Santiago Grau, P Acin, Sonia Luque, A Oliveras, J Pedro-Botet, E Navarrete-Rouco
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Alirocumab and evolocumab are two monoclonal antibodies proproteinconvertasesubtilisin/kexin type 9 inhibitors (iPCSK9) approved for the treatment of hypercholesterolaemia. Purpose Evaluation of the efficacy, safety and patient acceptance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19b10de4abc2e19dbf99d812937be2b9
https://doi.org/10.1136/ejhpharm-2019-eahpconf.173
https://doi.org/10.1136/ejhpharm-2019-eahpconf.173